Merck Says Blockbuster Keytruda Outperforms Chemotherapy in Advanced Endometrial Cancer Sahm
Onconic's Nesuparib Targets 26 Trillion Won Endometrial Cancer Market, Backed by SCI Paper Seoul Economic Daily
BackgroundPeople who menstruate may experience a range of symptoms, which, fluctuating throughout the different cycle phases, can interfere with their normal functioning. To date, research mostly investigated pain and psychological …
Rheumatic heart disease (RHD) remains the leading cause of acquired valvular heart disease in low- and middle-income countries, affecting an estimated 40 million individuals and disproportionately affecting children and young …
Endometriosis is a chronic, estrogen-dependent inflammatory disease that causes debilitating pain and significantly impairs quality of life. Due to its anti-inflammatory and immunomodulatory properties, vitamin D has been proposed as …
The causal role of established risk factors for premenstrual disorders (PMDs) remains unclear. We used Mendelian randomization (MR) to assess causality for eight known-risk factors identified through a literature review. …
Merck's (MRK) Keytruda Becomes First PD-1 Inhibitor To Beat Chemotherapy Alone In Endometrial Cancer Subtype londoninsider.co.uk
The Bose SoundLink Max just dropped to its lowest price to date — buy for $249 at Amazon Mashable
Merck touts Keytruda front-line win in endometrial cancer subtype, marking a PD-1 first Fierce Pharma
Summer Bloom Supports Women’s Health Dan’s Papers